# NovaBridge Biosciences: financial statements, quarterly

NBP · Nasdaq · CIK 1778016 · [Healthcare](/sectors/healthcare.md) · fiscal year ends Dec 31

Pages: [Overview](/companies/nbp.md) · [Financials](/companies/nbp/financials.md) · [Filings](/companies/nbp/filings.md) · [Insiders](/companies/nbp/insiders.md)

Standardized line items from XBRL company facts. Each value links to its filing; d marks a value derived from year-to-date figures. Other view: [annual](/companies/nbp/financials.md?period=annual).

## Balance sheet

| Line item | Unit | FY2019 (2019-12-31) | FY2020 (2020-12-31) | FY2021 (2021-12-31) | FY2022 (2022-12-31) | FY2023 (2023-12-31) | FY2024 (2024-12-31) | FY2025 (2025-12-31) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Cash and equivalents | $m | [163](/filings/0001193125-20-124785.md) | [729](/filings/0001193125-21-135440.md) | [553](/filings/0001193125-22-133550.md) | [343](/filings/0000950170-25-050344.md) | [292](/filings/0001778016-26-000002.md) | [68.3](/filings/0001778016-26-000002.md) | [211](/filings/0001778016-26-000002.md) |
| Current assets | $m | [196](/filings/0001193125-20-124785.md) | [819](/filings/0001193125-21-135440.md) | [750](/filings/0001193125-22-133550.md) | [526](/filings/0001104659-23-053462.md) | [330](/filings/0000950170-25-050344.md) | [177](/filings/0001778016-26-000002.md) | [218](/filings/0001778016-26-000002.md) |
| Total assets | $m | [250](/filings/0001193125-20-124785.md) | [971](/filings/0001193125-21-135440.md) | [879](/filings/0001193125-22-133550.md) | [591](/filings/0001104659-23-053462.md) | [369](/filings/0000950170-25-050344.md) | [213](/filings/0001778016-26-000002.md) | [261](/filings/0001778016-26-000002.md) |
| Current liabilities | $m | [84.5](/filings/0001193125-20-124785.md) | [88.3](/filings/0001193125-21-135440.md) | [97.9](/filings/0001193125-22-133550.md) | [110](/filings/0001104659-23-053462.md) | [58.1](/filings/0000950170-25-050344.md) | [8.5](/filings/0001778016-26-000002.md) | [26.9](/filings/0001778016-26-000002.md) |
| Total liabilities | $m | [96.0](/filings/0001193125-20-124785.md) | [108](/filings/0001193125-21-135440.md) | [163](/filings/0001193125-22-133550.md) | [169](/filings/0001104659-23-053462.md) | [126](/filings/0000950170-25-050344.md) | [11.5](/filings/0001778016-26-000002.md) | [29.6](/filings/0001778016-26-000002.md) |
| Short-term borrowings | $m | [7.2](/filings/0001193125-20-124785.md) | not reported | not reported | [2.7](/filings/0001104659-23-053462.md) | [4.2](/filings/0001104659-24-054452.md) | not reported | not reported |
| Shareholders' equity | $m | [(292)](/filings/0001193125-20-124785.md) | [862](/filings/0001193125-21-135440.md) | [715](/filings/0000950170-25-050344.md) | [418](/filings/0001778016-26-000002.md) | [243](/filings/0001778016-26-000002.md) | [201](/filings/0001778016-26-000002.md) | [231](/filings/0001778016-26-000002.md) |

- Cash and equivalents: us-gaap:CashAndCashEquivalentsAtCarryingValue
- Current assets: us-gaap:AssetsCurrent
- Total assets: us-gaap:Assets
- Current liabilities: us-gaap:LiabilitiesCurrent
- Total liabilities: us-gaap:Liabilities
- Short-term borrowings: us-gaap:ShortTermBorrowings
- Shareholders' equity: us-gaap:StockholdersEquity

Shares outstanding: 265,377,891 at 2025-12-31, from the cover of the [20-F/A filed 2026-06-16](/filings/0001778016-26-000006.md) (dei:EntityCommonStockSharesOutstanding).

Source: SEC EDGAR, XBRL company facts. Last ingested by Listed: Oct 24, 2026, 15:47 ET. No prices; not investment advice.